InsuLine Medical
Insulin Treatment Method
Company Overview
Snapshot
Founded in February 2007 by Gabriel Bitton, InsuLine Medical operated with 1–10 employees. The company raised a total of $6.5M across 4 funding rounds from 2 investors. A significant milestone for the company was its delisting from the TASE in June 2019, following its cessation of operations.
Business overview
InsuLine Medical developed solutions to enhance the effectiveness of existing insulin treatment methods by leveraging human physiology. Its primary product, the InsuPad, combined a disposable injection window with a reusable control unit that utilized skin-condition stabilization technology. By gently warming the skin, the device aimed to increase blood flow, thereby improving insulin absorption. The company's technology was noninvasive, safe, and had Medical Device Directive (CE mark) approval for the European Union. InsuLine Medical served the healthcare industry, targeting patients, physicians, and health insurance providers within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Drug Delivery.
Strategic signal
InsuLine Medical ceased operations in June 2019, leading to its delisting from the TASE. This event signals a complete halt in the company's activities and indicates a failure to sustain its business model or achieve further growth, marking a definitive end to its market presence.
Company Intelligence Q&A
- What was InsuLine Medical's primary product?
- InsuLine Medical's flagship product was the InsuPad, a device designed to improve insulin absorption by gently warming the skin at the injection site, thereby increasing blood flow.
- When did InsuLine Medical cease operations?
- InsuLine Medical ceased to operate in June 2019, which led to its delisting from the TASE.
- Did InsuLine Medical receive any funding from investors?
- Yes, InsuLine Medical raised funding from investors including IBI Investment House and Pontifax.
- Did InsuLine Medical have any international distribution agreements?
- In March 2016, InsuLine Medical signed a non-binding Memorandum of Understanding (MOU) to distribute its InsuPad product in Brazil.
- Did InsuLine Medical receive any grants for its technology?
- In March 2016, InsuLine Medical was set to receive funding from Israel's Chief Scientist for the use of its injection site treatment and stabilization technology with long-acting insulin.